Clinical trial
Lurtotecan Liposome in Treating Patients With Advanced Solid Tumors
NCT00003891 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00003891 |
|---|---|
| Title | Lurtotecan Liposome in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase I Study of NX211 Given as an IV Infusion Days 1, 2 and 3 Every 3 Weeks in Patients With Solid Tumors |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Collaborators | Nexstar Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | lurtotecan liposome |
| Enrollment | 37 |
| Start date | Feb 25, 1999 |
| Primary completion | Jun 8, 2001 |
| Completion | Sep 22, 2008 |
| First posted | Jun 17, 2004 |
| Last update posted | Apr 9, 2020 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: